<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The evaluation of comorbidity is of increasing importance in patients with <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: In the present study, the influence of comorbidity on survival and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) evolution was analyzed retrospectively in 419 patients with de novo <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (observation period: 1985-2007) </plain></SENT>
<SENT sid="2" pm="."><plain>The median age was 71 years (range 24-91 years) </plain></SENT>
<SENT sid="3" pm="."><plain>Two different scoring systems, the hematopoietic stem-cell transplantation-specific comorbidity index (HCT-CI) and the Charlson comorbidity index (CCI) were applied </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The HCT-CI was found to be a significant prognostic factor for overall survival (OS, P &lt; 0.05) as well as event-free survival (EFS, P &lt; 0.05) in our patients, whereas the CCI was of prognostic significance for OS (P &lt; 0.05), but not for EFS </plain></SENT>
<SENT sid="5" pm="."><plain>For <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-free survival, neither the HCT-CI nor the CCI were of predictive value </plain></SENT>
<SENT sid="6" pm="."><plain>A multivariate analysis including age, <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase, ferritin, karyotype, number of cytopenias, French-American-British groups, and comorbidity was applied </plain></SENT>
<SENT sid="7" pm="."><plain>Comorbidity was found to be an independent prognostic factor in patients with low- or int-1-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (P &lt; 0.05) regarding OS and EFS </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Together, our data show that comorbidity is an important risk factor for OS and EFS in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>